The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Novel treatment approaches in BPDCN: the promise of CD123-targeting allogeneic CAR-T cells
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York, NY, discusses novel treatment approaches for blastic plasmacytoid dendritic cell neoplasm (BPDCN), drawing focus on the promise of CD123-targeting agents. Prof. Konopleva first comments on the approval of tagraxofusp in BPDCN and the efficacy of this agent, and then goes on to explain the role of CAR-T cells in this space. To conclude, Prof. Konopleva shares some insights into a pre-clinical study evaluating CD123-targeting allogeneic CAR-T cells in BPDCN, and the impact that these agents may have on the BPDCN treatment landscape. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
